BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 4, 2013--
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B.
Siegall, Ph.D., President and Chief Executive Officer, will present at
the Morgan Stanley Global Healthcare Conference on Tuesday, September
10, 2013, at 2:05 p.m. Eastern Time. The presentation will be webcast
live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com
in the Investors
and News section.
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development
and commercialization of monoclonal antibody-based therapies for the
treatment of cancer. The company’s lead program, ADCETRIS®
(brentuximab vedotin), received accelerated approval from the U.S. Food
and Drug Administration in August 2011 and approval with conditions from
Health Canada in February 2013 for two indications. In addition, under a
collaboration with Millennium: The Takeda Oncology Company, ADCETRIS
received conditional approval from the European Commission in October
2012. Seattle Genetics is also advancing a robust pipeline of
clinical-stage ADC programs: SGN-75, ASG-22ME, SGN-CD19A, SGN-CD33A,
ASG-15ME and SGN-LIV1A. Seattle Genetics has collaborations for its ADC
technology with a number of leading biotechnology and pharmaceutical
companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer,
Celldex, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer
and Progenics, as well as ADC co-development agreements with Agensys and
Genmab. More information can be found at www.seattlegenetics.com.
Source: Seattle Genetics, Inc.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160